VivoSeq
Metabolic & Endocrine

Hemochromatosis

7

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Hemochromatosis is an early-stage landscape with 7 programs across 4 companies. The most active players are Alnylam Pharmaceuticals, Novartis, Chiesi Farmaceutici S.p.A.. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

50/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Novartis logo

Novartis

1 program

ApprovedChiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

1 program

ApprovedV

Veloxis Pharmaceuticals

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Terminated1 · 50%

Clinical Trials

Trial Activity

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00000595
Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study
Terminated·RRennes University Hospital·Phase 2·NCT02263638·17 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)